Home / Pharmaceuticals / Treatment-Resistant Depression (TRD) Treatment Market By Drug Class (Selective Serotonin Reuptake Inhibitors, Monoamine Oxidase Inhibitors, Tricyclic Antidepressant, Esketamine Nasal Spray) - Growth, Future Prospects And Competitive Analysis, 2019 - 2027

Treatment-Resistant Depression (TRD) Treatment Market By Drug Class (Selective Serotonin Reuptake Inhibitors, Monoamine Oxidase Inhibitors, Tricyclic Antidepressant, Esketamine Nasal Spray) - Growth, Future Prospects And Competitive Analysis, 2019 - 2027

Published: Aug 2019 | Report Code: 58359-08-19

Industry Outlook

The treatment-resistant depression treatment market is set to reach from US$ 1,010.6 Mn in 2018 to US$ 1,389.3 Mn exhibiting good growth at a compounded annual growth rate (CAGR) of 3.6% during the forecast period from 2019 to 2027. Depression is the most common mental disorder affecting approximately 300 million people worldwide. The prevalence rate is high in women in comparison to men. In the last 2 decades there has been significant rise in the number of ailing patients showing resistance to first line therapy drugs for treating depression. Recently USFDA gave approval to Esketamine nasal sprays for treating TRD. Currently AXS-05 drug developed by Axsome Therapeutics, Inc., is under phase III clinical trial investigation for its application in treating TRD.

Market Synopsis

Treatment-Resistant Depression (TRD) Treatment Market

Recent USFDA approval of Spravato (esketamine nasal spray) will register impressive growth during the forecast period

In one third of the patients suffering with depression treatment resistant in encountered when patients fail to respond to first line therapy drugs. The underlying factor responsible for this resistance is not known, accurate diagnosis and identification of possible cormorbid condition determines treatment resistant depression (TRD) in ailing patients worldwide. The treatment regimen followed is prescribing drugs such as SSRI’s, MAOI’s, tricyclic antidepressant and serotonin 1A receptor agonist for treating TRD. Increasing the dose of prescribed medicine to maximum toleration level, combination of antidepressants or switching to different class of antidepressant is the best possible and conventional method adopted in its treatment globally. Recently USFDA has approved Esketamine nasal spray (Spravato) developed by Janssen Pharmaceutical, Inc., as the novel prescription drug for treating TRD in conjunction with an oral antidepressant. Researchers anticipate its faster adoption rate owing to its excellent pharmacokinetic and pharmacodynamic profile observed during clinical trial investigation.

Treatment-Resistant Depression (TRD) Treatment Market

Growing incidence of depression and anxiety to drive the market growth in North America region

North America with a share of 34.2% is dominating the regional segment for treatment-resistant depression treatment market. According to the latest statistics provided by Center for Disease Control and Prevention (CDC) the incidence rate of suicidal deaths is 14.5 per 100,000 people in the United States. Affordable reimbursement scenario for the drugs employed in treating mental disorders further propels the market growth in the region. In the second place is Europe representing a market share of 30.5% owing to the domicile of key players such as Novartis AG, Janssen Pharmaceuticals, Inc., Pfizer, Inc., Mylan Pharmaceuticals, Inc. etc. Asia Pacific is currently holding 17.3% market share on account of rising prevalence of mental disorders, effective implementation of treatment regiment to treat depression and suicidal tendency across all age groups.

Treatment-Resistant Depression (TRD) Treatment Market

Historical & Forecast Period

2017 – Historical Year

2018 – Base Year

2019-2027 – Forecast Period

This research report presents the analysis of each segment from 2017 to 2027 considering 2018 as the base year for the research. Compounded annual growth rate (CAGR) for each respective segments are calculated for the forecast period from 2019 to 2027.

Treatment-Resistant Depression (TRD) Treatment Market

Report Scope by Segments

The market is segmented by drug class and by geography.

By Drug Class (2017–2027; US$ Mn)

  • Selective Serotonin Reuptake Inhibitors (SSRI’s)
  • Monoamine Oxidase Inhibitors (MAOI’s)
  • Tricyclic Antidepressant
  • Serotonin 1A Receptor Agonist
  • Esketamine Nasal Spray

Geography Segment (2017–2027; US$ Mn)

  • North America
    • United States
    • Canada
  • Europe
    • United Kingdom
    • Germany
    • Rest of Europe
  • Asia Pacific (APAC)
    • China
    • Japan
    • Rest of APAC
  • Latin America (LATAM)
    • Brazil
    • Mexico
    • Rest of Latin America
  • Middle East and Africa (MEA)
    • GCC
    • Rest of Middle East and Africa

Pharmaceutical companies manufacturing drugs for the treatment regimen of treatment-resistant depression are Bristol Myers Squibb Company, Eli Lilly & Company, Janssen Pharmaceuticals, Inc., Mylan Pharmaceuticals, Inc., Novartis AG, Otsuka Pharmaceutical Co., Ltd., Pfizer, Inc., Valeant Pharmaceuticals International, Validus Pharmaceuticals LLC and Wyeth.

Key questions answered in this report

  • Which pharmaceutical companies are actively engaged in providing medicine for the treatment of TRD?
  • What are the drivers, restraints and opportunities associated with TRD treatment market?
  • What is the treatment regimen adopted by psychiatrist for the treatment of TRD worldwide?
  • What is the prevalence rate of TRD in different regional segments throughout the globe?

Chapter 1. Preface
1.1. Report Scope and Description
1.1.1. Purpose of the Report
1.1.2. Target Audience
1.1.3. USP and Key Treatment
1.2. Research Scope
1.3. Research Methodology
1.3.1. Phase I-Secondary Research
1.3.2. Phase II-Primary Research
1.3.3. Approach Adopted
1.3.4. Top-down Approach
1.3.5. Bottom-up Approach
1.3.6. Phase III-Expert Panel Review
1.3.7. Assumptions
1.4. Market Segmentation

Chapter 2. Executive Summary
2.1. Global Treatment-Resistant Depression Treatment Market Portraiture
2.2. Global Treatment-Resistant Depression Treatment Market, by Drug Class, 2018 (US$ Mn)
2.3. Global Treatment-Resistant Depression Treatment Market, by Geography, 2018 (US$ Mn)

Chapter 3. Treatment-Resistant Depression Treatment Market: Dynamics and Future Outlook
3.1. Market Overview
3.2. Drivers
3.3. Challenges
3.4. Opportunities
3.5. Attractive Investment Proposition, by Geography, 2018
3.6. Competitive Analysis: Global Treatment-Resistant Depression Treatment Market, by Key Players, 2018

Chapter 4. Global Treatment-Resistant Depression Treatment Market, by Drug Class
4.1. Overview
4.2. Selective Serotonin Reuptake Inhibitors
4.3. Monoamine Oxidase Inhibitors
4.4. Tricyclic Antidepressant
4.5. Serotonin 1A Receptor Agonist
4.6. Esketamine Nasal Spray
4.7. Pipeline Analysis
4.7.1. Phase III Drug
4.7.1.1. AXS-05
4.7.2. Tabular Representation of Phase II and I Drugs

Chapter 5. Global Treatment-Resistant Depression Treatment Market, by Geography
5.1. Overview
5.2. North America Treatment-Resistant Depression Treatment Market Analysis, 2017 – 2027
5.2.1. North America Treatment-Resistant Depression Treatment Market, by Drug Class, 2017 – 2027 (US$ Mn)
5.2.2. North America Treatment-Resistant Depression Treatment Market, by Country, 2017 – 2027 (US$ Mn)
5.2.2.1. U.S.
5.2.2.2. Canada
5.3. Europe Treatment-Resistant Depression Treatment Market Analysis, 2017– 2027
5.3.1. Europe Treatment-Resistant Depression Treatment Market, by Drug Class, 2017 – 2027 (US$ Mn)
5.3.2. Europe Treatment-Resistant Depression Treatment Market, by Country/Region, 2017 – 2027 (US$ Mn)
5.3.2.1. U.K.
5.3.2.2. Germany
5.3.2.3. Rest of Europe
5.4. Asia Pacific Treatment-Resistant Depression Treatment Market Analysis, 2017 – 2027
5.4.1. Asia Pacific Treatment-Resistant Depression Treatment Market, by Drug Class, 2017 – 2027 (US$ Mn)
5.4.2. Asia Pacific Treatment-Resistant Depression Treatment Market, by Country/Region, 2017 – 2027 (US$ Mn)
5.4.2.1. China
5.4.2.2. Japan
5.4.2.3. Rest of Asia Pacific
5.5. Latin America Treatment-Resistant Depression Treatment Market Analysis, 2017 – 2027
5.5.1. Latin America Treatment-Resistant Depression Treatment Market, by Drug Class, 2017 – 2027 (US$ Mn)
5.5.2. Latin America Treatment-Resistant Depression Treatment Market, by Country/Region, 2017 – 2027 (US$ Mn)
5.5.2.1. Brazil
5.5.2.2. Mexico
5.5.2.3. Rest of Latin America
5.6. Middle East & Africa Treatment-Resistant Depression Treatment Market Analysis, 2017 – 2027
5.6.1. MEA Treatment-Resistant Depression Treatment Market, by Drug Class, 2017 – 2027 (US$ Mn)
5.6.2. MEA Treatment-Resistant Depression Treatment Market, by Region, 2017– 2027 (US$ Mn)
5.6.2.1. GCC
5.6.2.2. Rest of MEA

Chapter 6. Company Profiles
6.1. Bristol Myers Squibb Company
6.1.1. Business Description
6.1.2. Financial Information (Subject to data availability)
6.1.3. Product Portfolio
6.1.4. News Coverage
6.2. Eli Lilly & Company
6.3. Janssen Pharmaceutcials, Inc.
6.4. Mylan Pharmaceutcials, Inc.
6.5. Novartis AG
6.6. Otsuka Pharmaceutical Co., Ltd.
6.7. Pfizer, Inc.
6.8. Valeant Pharmaceuticals International
6.9. Validus Pharmaceuticals LLC
6.10. Wyeth

FIG. 1 Treatment-Resistant Depression Treatment Market: Research Methodology
FIG. 2 Treatment-Resistant Depression Treatment: Market Segmentation
FIG. 3 Global Treatment-Resistant Depression Treatment Market, by Drug Class, 2018 (US$ Mn)
FIG. 4 Global Treatment-Resistant Depression Treatment Market, by Geography, 2018 (US$ Mn)
FIG. 5 Attractive Investment Proposition: by Geography, 2018
FIG. 6 Competitive Analysis: Global Treatment-Resistant Depression Treatment Market, by Key Players, 2018
FIG. 7 Global Selective Serotonin Reuptake Inhibitors Market for Treatment-Resistant Depression Treatment, 2017 – 2027 (US$ Mn)
FIG. 8 Global Monoamine Oxidase Inhibitors Market for Treatment-Resistant Depression Treatment, 2017 – 2027 (US$ Mn)
FIG. 9 Global Tricyclic Antidepressant Market for Treatment-Resistant Depression Treatment, 2017 – 2027 (US$ Mn)
FIG. 10 Global Serotonin 1A Receptor Agonist Market for Treatment-Resistant Depression Treatment, 2017– 2027 (US$ Mn)
FIG. 11 Global Esketamine Nasal Spray Market for Treatment-Resistant Depression Treatment, 2017 – 2027 (US$ Mn)
FIG. 12 U.S. Treatment-Resistant Depression Treatment Market, 2017 – 2027 (US$ Mn)
FIG. 13 Canada Treatment-Resistant Depression Treatment Market, 2017 – 2027 (US$ Mn)
FIG. 14 U.K. Treatment-Resistant Depression Treatment Market, 2017 – 2027 (US$ Mn)
FIG. 15 Germany Treatment-Resistant Depression Treatment Market, 2017 – 2027 (US$ Mn)
FIG. 16 Rest of Europe Treatment-Resistant Depression Treatment Market, 2017 – 2027 (US$ Mn)
FIG. 17 China Treatment-Resistant Depression Treatment Market, 2017– 2027 (US$ Mn)
FIG. 18 Japan Treatment-Resistant Depression Treatment Market, 2017 – 2027 (US$ Mn)
FIG. 19 Rest of Asia Pacific Treatment-Resistant Depression Treatment Market, 2017 – 2027 (US$ Mn)
FIG. 20 Brazil Treatment-Resistant Depression Treatment Market, 2017 – 2027 (US$ Mn)
FIG. 21 Mexico Treatment-Resistant Depression Treatment Market, 2017 – 2027 (US$ Mn)
FIG. 22 Rest of Latin America Treatment-Resistant Depression Treatment Market, 2017 – 2027 (US$ Mn)
FIG. 23 GCC Treatment-Resistant Depression Treatment Market, 2017 – 2027 (US$ Mn)
FIG. 24 Rest of Middle East and Africa Treatment-Resistant Depression Treatment Market, 2017 – 2027 (US$ Mn)

TABLE 1 Global Treatment-Resistant Depression Treatment Market Portraiture
TABLE 2 Global Treatment-Resistant Depression Treatment Market, by Drug Class, 2017 – 2027 (US$ Mn)
TABLE 3 Global Treatment-Resistant Depression Treatment Market, by Geography, 2017 – 2027 (US$ Mn)
TABLE 4 North America Treatment-Resistant Depression Treatment Market, by Drug Class, 2017 – 2027 (US$ Mn)
TABLE 5 North America Treatment-Resistant Depression Treatment Market, by Country, 2017 – 2027 (US$ Mn)
TABLE 6 Europe Treatment-Resistant Depression Treatment Market, by Drug Class, 2017 – 2027 (US$ Mn)
TABLE 7 Europe Treatment-Resistant Depression Treatment Market, by Country/Region, 2017– 2027 (US$ Mn)
TABLE 8 Asia Pacific Treatment-Resistant Depression Treatment Market, by Drug Class, 2017 – 2027 (US$ Mn)
TABLE 9 Asia Pacific Treatment-Resistant Depression Treatment Market, by Country/Region, 2017 – 2027 (US$ Mn)
TABLE 10 Latin America Treatment-Resistant Depression Treatment Market, by Drug Class, 2017 – 2027 (US$ Mn)
TABLE 11 Latin America Treatment-Resistant Depression Treatment Market, by Country/Region, 2017 – 2027 (US$ Mn)
TABLE 12 Middle East and Africa Treatment-Resistant Depression Treatment Market, by Drug Class, 2017– 2027 (US$ Mn)
TABLE 13 Middle East and Africa Treatment-Resistant Depression Treatment Market, by Region, 2017 – 2027 (US$ Mn)
TABLE 14 Bristol Myers Squibb Company: Company Snapshot (Business Description; Financial Information; Product Portfolio; Key Developments)
TABLE 15 Eli Lilly & Company: Company Snapshot (Business Description; Financial Information; Product Portfolio; Key Developments)
TABLE 16 Janssen Pharmaceuticals, Inc.: Company Snapshot (Business Description; Financial Information; Product Portfolio; Key Developments)
TABLE 17 Mylan Pharmaceutcials, Inc.: Company Snapshot (Business Description; Financial Information; Product Portfolio; Key Developments)
TABLE 18 Novartis AG: Company Snapshot (Business Description; Financial Information; Product Portfolio; Key Developments)
TABLE 19 Otsuka Pharmaceutcials Co., Ltd.: Company Snapshot (Business Description; Financial Information; Product Portfolio; Key Developments)
TABLE 20 Pfizer, Inc.: Company Snapshot (Business Description; Financial Information; Product Portfolio; Key Developments)
TABLE 21 Valeant Pharmaceutcials International: Company Snapshot (Business Description; Financial Information; Product Portfolio; Key Developments)
TABLE 22 Validus Pharmaceuticals LLC.: Company Snapshot (Business Description; Financial Information; Product Portfolio; Key Developments)
TABLE 23 Wyeth: Company Snapshot (Business Description; Financial Information; Product Portfolio; Key Developments)

Choose License Type
Connect With Us
+1-800-361-8290
24/7 Research Support

Our Clients